The FINANCIAL — Teva Pharmaceutical Industries Ltd., on October 12 announced the exclusive launch of the generic equivalent to Avodart (dutasteride) capsules, 0.5 mg, in the United States.
Dutasteride is a 5 alpha-reductase enzyme inhibitor and works by lowering production of a hormone called dihydrotestosterone (DHT). Dutasteride capsules are used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate, according to Teva.
Teva was first to file and expects to be exclusive for several weeks.
Avodart (dutasteride) capsules, marketed by GlaxoSmithKline, had annual sales of approximately $467 million in the United States, according to IMS data as of July 2015.